Issues related to prior authorization; ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) model
2026 · 1st Quarter (Jan 1 - Mar 31)
THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Filed by THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES).
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- Not reported
- Expenses
- $3,490,000.00
- Filing UUID
- 8b0c29d9-e6af-4e47-8953-6c568a1ec49e
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues relating to implementation of the No Surprises Act
H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act
Literal federal measure citations: H.R. 3838, S2296, HR. 6400, S. 4106
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
Literal federal measure citations: S. 1542, H.R.2214, H.R. 5378, S. 1339, S.526, H.R.7148, H.R. 5582, S. 2355
Issues related to competition in the health care marketplace.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.